Mereo BioPharma Group plc (MREO) has a negative trailing P/E of -1.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 3.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -82.35%, forward earnings yield 32.47%.
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.1 | 0.00 | 0.73 | 0.00 | - |
| 2017 | -2.3 | 0.82 | 1.44 | -27.31 | - |
| 2018 | -2.9 | 0.12 | 2.82 | 0.00 | - |
| 2019 | -1.3 | 0.13 | 1.10 | 0.00 | - |
| 2020 | -1.2 | -0.04 | -11.85 | 0.00 | - |
| 2021 | 10.9 | -0.10 | 1.57 | 3.80 | - |
| 2022 | -2.1 | 0.01 | 1.76 | 0.00 | - |
| 2023 | -10.3 | 0.28 | 6.03 | 30.47 | - |
| 2024 | -12.0 | 0.12 | 8.49 | 0.00 | - |
| 2025 | -1.6 | 0.14 | 1.62 | 132.86 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-19,553.90 | $0.00 | $-28.39M | - |
| 2017 | $-19,003.80 | $-3.29M | $-38.8M | - |
| 2018 | $-14,352.90 | $0.00 | $-32.03M | - |
| 2019 | $-12,902.60 | $-122K | $-34.84M | - |
| 2020 | $-16,503.30 | $393K | $-163.63M | -41635.6% |
| 2021 | $749.65 | $36.46M | $12.73M | 34.9% |
| 2022 | $-1,750.35 | $1.51M | $-34.2M | -2269.1% |
| 2023 | $-1,100.22 | $10M | $-29.47M | -294.7% |
| 2024 | $-0.29 | $0.00 | $-43.25M | - |
| 2025 | $-0.26 | $500K | $-41.88M | -8375.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.01 | $-0.10 – $0.03 | $18.44M | $16.85M – $20.02M | 4 |
| 2027 | $-0.01 | $-0.01 – $-0.01 | $22.89M | $19.17M – $26.61M | 3 |
| 2028 | $0.05 | $0.04 – $0.07 | $40.29M | $40.19M – $40.4M | 2 |
| 2029 | $-0.05 | $-0.06 – $-0.04 | $43.55M | $37.85M – $49.26M | 1 |
| 2030 | $0.00 | $0.00 – $0.00 | $103.02M | $89.52M – $116.51M | 0 |
